| Year |
Citation |
Score |
| 2023 |
Russell PA, Farrall AL, Prabhakaran S, Asadi K, Barrett W, Cooper C, Cooper W, Cotton S, Duhig E, Egan M, Fox S, Godbolt D, Gupta S, Hassan A, Leslie C, et al. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study. Pathology. PMID 37833206 DOI: 10.1016/j.pathol.2023.08.008 |
0.626 |
|
| 2023 |
Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, ... ... Fox SB, et al. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group. The Journal of Pathology. PMID 37608772 DOI: 10.1002/path.6155 |
0.337 |
|
| 2023 |
Takano EA, Younes MM, Meehan K, Spalding L, Yan M, Allan P, Fox SB, Redfern A, Clouston D, Giles GG, Christie EL, Anderson RL, Zethoven M, Phillips KA, Gorringe K, et al. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival. Bmc Cancer. 23: 459. PMID 37208678 DOI: 10.1186/s12885-023-10795-5 |
0.365 |
|
| 2023 |
Deb S, Chakrabarti A, Fox SB. Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers. 15. PMID 36831687 DOI: 10.3390/cancers15041346 |
0.332 |
|
| 2022 |
Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, ... ... Fox S, et al. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. European Journal of Cancer (Oxford, England : 1990). 173: 178-193. PMID 35933885 DOI: 10.1016/j.ejca.2022.06.011 |
0.317 |
|
| 2022 |
van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S. Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research : Bcr. 24: 50. PMID 35841108 DOI: 10.1186/s13058-022-01539-7 |
0.307 |
|
| 2022 |
Doig KD, Fellowes A, Scott P, Fox SB. Tumour mutational burden: an overview for pathologists. Pathology. PMID 35153070 DOI: 10.1016/j.pathol.2021.11.008 |
0.773 |
|
| 2021 |
Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, ... ... Fox SB, et al. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology. PMID 34937664 DOI: 10.1016/j.pathol.2021.11.002 |
0.549 |
|
| 2021 |
Bouchè V, Aldegheri G, Donofrio CA, Fioravanti A, Roberts-Thomson S, Fox SB, Schettini F, Generali D. BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives? Frontiers in Oncology. 11: 772052. PMID 34804975 DOI: 10.3389/fonc.2021.772052 |
0.484 |
|
| 2021 |
Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Archiv : An International Journal of Pathology. PMID 34458944 DOI: 10.1007/s00428-021-03190-7 |
0.349 |
|
| 2020 |
Kalaw E, Lim M, Kutasovic JR, Sokolova A, Taege L, Johnstone K, Bennett J, Saunus JM, Niland C, Ferguson K, Gresshoff I, Bettington M, Pathmanathan N, Tse GM, Papadimos D, ... ... Fox S, et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. British Journal of Cancer. PMID 32939056 DOI: 10.1038/s41416-020-01065-3 |
0.318 |
|
| 2020 |
van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research : Bcr. 22: 91. PMID 32811538 DOI: 10.1186/s13058-020-01328-0 |
0.346 |
|
| 2020 |
Cheasley D, Devereux L, Hughes S, Nickson C, Procopio P, Lee G, Li N, Pridmore V, Elder K, Bruce Mann G, Kader T, Rowley SM, Fox SB, Byrne D, Saunders H, et al. The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. Npj Breast Cancer. 6: 34. PMID 32802943 DOI: 10.1038/s41523-020-00176-7 |
0.358 |
|
| 2020 |
Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, ... ... Fox SB, et al. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment. PMID 32770287 DOI: 10.1007/s10549-020-05856-3 |
0.766 |
|
| 2020 |
Whittle JR, Vaillant F, Surgenor E, Policheni AN, Giner G, Capaldo BD, Chen HR, Liu HK, Dekkers JF, Sachs N, Clevers H, Fellowes A, Green T, Xu H, Fox SB, et al. Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32245900 DOI: 10.1158/1078-0432.Ccr-19-1872 |
0.346 |
|
| 2020 |
Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, Fox SB, Giudici F, Generali D. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. PMID 32060782 DOI: 10.1007/s10549-020-05565-x |
0.552 |
|
| 2020 |
Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, et al. The 2019 WHO classification of tumours of the breast. Histopathology. PMID 32056259 DOI: 10.1111/his.14091 |
0.313 |
|
| 2019 |
Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, Henderson MA, Nightingale SS, Ho KM, Myles PS, Fox S, Riedel B, Sloan EK. Pre-operative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II randomized trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31754048 DOI: 10.1158/1078-0432.CCR-19-2641 |
0.308 |
|
| 2019 |
Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology. PMID 31668406 DOI: 10.1016/j.pathol.2019.08.006 |
0.627 |
|
| 2019 |
Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, ... Fox S, et al. Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research. 79: 3008. PMID 31160311 DOI: 10.1158/0008-5472.Can-19-1133 |
0.305 |
|
| 2019 |
Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, et al. Combined tumor sequencing and case/control analyses of RAD51C in breast cancer. Journal of the National Cancer Institute. PMID 30949688 DOI: 10.1093/Jnci/Djz045 |
0.342 |
|
| 2019 |
Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, ... Fox SB, et al. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. The Journal of Pathology. PMID 30843206 DOI: 10.1002/path.5262 |
0.339 |
|
| 2018 |
McCart Reed AE, Kalaw E, Nones K, Bettington M, Lim M, Bennett J, Johnstone K, Kutasovic JR, Saunus JM, Kazakoff S, Xu Q, Wood S, Holmes O, Leonard C, Reid LE, ... ... Fox S, et al. Phenotypic and molecular dissection of Metaplastic Breast Cancer and the prognostic implications. The Journal of Pathology. PMID 30350370 DOI: 10.1002/path.5184 |
0.374 |
|
| 2018 |
Kader T, Hill P, Opeskin K, Goode D, Elder K, Pang J, Fox S, Mann G, Campbell I, Gorringe K. Abstract PD1-12: Identification of copy number alterations associated with the progression of high risk premalignant breast lesions to breast carcinoma Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd1-12 |
0.336 |
|
| 2018 |
Gorringe K, Hughes S, Nickson C, Devereux L, Pridmore V, Rowley S, Byrne D, Cheasley D, Kavanagh A, Mann G, Fox S, Campbell I. Abstract P3-04-06: Genomic analysis of cancers arising in breasts with different mammographic density Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-04-06 |
0.345 |
|
| 2017 |
Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA, Clyne C, Gorringe KL, Dobrovic A, Fox SB. LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget. 8: 83626-83636. PMID 29137369 DOI: 10.18632/oncotarget.18886 |
0.409 |
|
| 2017 |
Gorringe KL, Fox SB. Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. Frontiers in Oncology. 7: 248. PMID 29109942 DOI: 10.3389/fonc.2017.00248 |
0.324 |
|
| 2017 |
Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881. PMID 29108271 DOI: 10.18632/oncotarget.20239 |
0.813 |
|
| 2017 |
Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB. BRCA2 carriers with male breast cancer show elevated tumour methylation. Bmc Cancer. 17: 641. PMID 28893223 DOI: 10.1186/s12885-017-3632-7 |
0.329 |
|
| 2017 |
Paquet-Fifield S, Roufail S, Zhang YF, Sofian T, Byrne DJ, Coughlin PB, Fox SB, Stacker SA, Achen MG. The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. Growth Factors (Chur, Switzerland). 1-15. PMID 28697634 DOI: 10.1080/08977194.2017.1349765 |
0.312 |
|
| 2017 |
Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in Triple Negative Breast Cancers. Histopathology. PMID 28211079 DOI: 10.1111/his.13187 |
0.37 |
|
| 2017 |
Jeffreena Miranda P, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, et al. MDM4 is a rational target for treating breast cancers with mutant p53. The Journal of Pathology. PMID 28097652 DOI: 10.1002/path.4877 |
0.351 |
|
| 2016 |
Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. PMID 28049579 DOI: 10.1016/j.pathol.2016.10.010 |
0.372 |
|
| 2016 |
Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, et al. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". Plos Medicine. 13: e1002204. PMID 28027312 DOI: 10.1371/journal.pmed.1002204 |
0.311 |
|
| 2016 |
Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. The Lancet. Oncology. PMID 27964843 DOI: 10.1016/S1470-2045(16)30631-3 |
0.383 |
|
| 2016 |
Huo CW, Waltham M, Khoo C, Fox SB, Hill P, Chen S, Chew GL, Price JT, Nguyen CH, Williams ED, Henderson M, Thompson EW, Britt KL. Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. Breast Cancer Research : Bcr. 18: 106. PMID 27776557 DOI: 10.1186/s13058-016-0767-4 |
0.319 |
|
| 2016 |
Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, von Neumann-Cosel V, Bilous M. Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. Pathology. PMID 27567228 DOI: 10.1016/j.pathol.2016.05.007 |
0.329 |
|
| 2016 |
Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, ... Fox SB, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. Breast (Edinburgh, Scotland). 29: 55-61. PMID 27428471 DOI: 10.1016/j.breast.2016.07.003 |
0.742 |
|
| 2016 |
Roviello G, Ravelli A, Ida Fiaschi A, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D. Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology & Hepatology. PMID 27376400 DOI: 10.1080/17474124.2016.1209407 |
0.485 |
|
| 2016 |
Roviello G, Ravelli A, Barni S, Petrelli F, Bottini A, Fox SB, Generali D. Is it time for everolimus-based combination in castration-resistant prostate cancer? Future Oncology (London, England). PMID 27250597 DOI: 10.2217/fon-2016-0136 |
0.444 |
|
| 2016 |
Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone CN, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, ... Fox SB, et al. E3 ligase E6AP represses breast cancer metastasis via regulation of ECT2-Rho signalling. Cancer Research. PMID 27231202 DOI: 10.1158/0008-5472.Can-15-1553 |
0.4 |
|
| 2016 |
Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer (Oxford, England : 1990). 61: 111-121. PMID 27162152 DOI: 10.1016/j.ejca.2016.04.002 |
0.467 |
|
| 2016 |
Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 68: 110-8. PMID 26768033 DOI: 10.1111/his.12862 |
0.309 |
|
| 2015 |
Huang KT, Mikeska T, Li J, Takano EA, Millar EK, Graham PH, Boyle SE, Campbell IG, Speed TP, Dobrovic A, Fox SB. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. Bmc Cancer. 15: 669. PMID 26452468 DOI: 10.1186/s12885-015-1676-0 |
0.331 |
|
| 2015 |
Cappelletti MR, Gnetti L, Santini D, Spada D, Fox SB, Generali D. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? Oncoscience. 2: 567-9. PMID 26244161 DOI: 10.18632/ONCOSCIENCE.168 |
0.497 |
|
| 2015 |
Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Ying Lee Y, Hiddingh S, Rogers TM, Teunisse AF, Herold MJ, Marine JC, Fox SB, Jochemsen A, et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death & Disease. 6: e1821. PMID 26181202 DOI: 10.1038/cddis.2015.173 |
0.377 |
|
| 2015 |
Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology. PMID 26118394 DOI: 10.1111/his.12765 |
0.543 |
|
| 2015 |
Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, et al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute. Monographs. 2015: 90-6. PMID 26063896 DOI: 10.1093/jncimonographs/lgv023 |
0.622 |
|
| 2015 |
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, ... ... Fox SB, et al. Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response. Journal of the National Cancer Institute. Monographs. 2015: 64-6. PMID 26063890 DOI: 10.1093/jncimonographs/lgv018 |
0.791 |
|
| 2015 |
Generali D, Fox SB, Cristofanilli M, Bianchini G, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M. Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute. Monographs. 2015: 1-3. PMID 26063875 DOI: 10.1093/jncimonographs/lgv022 |
0.485 |
|
| 2015 |
Takano EA, Hunter SM, Campbell IG, Fox SB. Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. Journal of Clinical Pathology. 68: 362-7. PMID 25713418 DOI: 10.1136/jclinpath-2014-202824 |
0.311 |
|
| 2015 |
Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, ... ... Fox SB, et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. British Journal of Cancer. 112: 52-60. PMID 25461806 DOI: 10.1038/bjc.2014.563 |
0.819 |
|
| 2014 |
Kato T, Pezzella F, Steers G, Campo L, Leek RD, Turley H, Kameoka S, Nishikawa T, Harris AL, Gatter KC, Fox S. Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology. 7: 7967-78. PMID 25550840 |
0.819 |
|
| 2014 |
Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T, Fellowes A, Dobrovic A, Fox SB. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. British Journal of Cancer. 111: 2351-60. PMID 25490678 DOI: 10.1038/bjc.2014.511 |
0.305 |
|
| 2014 |
Trabert B, Falk RT, Figueroa JD, Graubard BI, Garcia-Closas M, Lissowska J, Peplonska B, Fox SD, Brinton LA. Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland. Cancer Causes & Control : Ccc. 25: 1587-93. PMID 25189422 DOI: 10.1007/s10552-014-0461-8 |
0.307 |
|
| 2014 |
Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. British Journal of Cancer. 111: 46-54. PMID 24874483 DOI: 10.1038/bjc.2014.236 |
0.633 |
|
| 2014 |
Bedussi F, Bottini A, Memo M, Fox SB, Sigala S, Generali D. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall? Expert Opinion On Therapeutic Targets. 18: 665-78. PMID 24833241 DOI: 10.1517/14728222.2014.898064 |
0.588 |
|
| 2014 |
Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, ... ... Fox SB, et al. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". Breast Cancer Research and Treatment. 144: 113-21. PMID 24469643 DOI: 10.1007/s10549-014-2840-y |
0.544 |
|
| 2014 |
Deb S, Johansson I, Byrne D, Nilsson C, Investigators k, Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB. Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 27: 1223-30. PMID 24457463 DOI: 10.1038/Modpathol.2013.231 |
0.33 |
|
| 2014 |
Masoud Rahbari R, Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski J, Verschoor S, KA Miller E, Van der Spek P, Reis-Filho J, Ramsay R, O'Toole S, McNeil C, ... ... Fox S, et al. Enhanced RAD21 Cohesin Expression Confers Poor Prognosis and Resistance to Chemotherapy in High Grade Luminal, Basal, and HER 2 Breast Cancers International Journal of Radiation Oncology*Biology*Physics. 90: S812. DOI: 10.1016/J.IJROBP.2014.05.2343 |
0.358 |
|
| 2013 |
Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, Kyle FJ, Thomas RS, Launchbury R, Hua H, Callaghan HB, Carroll JS, Charles Coombes R, Zwart W, Buluwela L, et al. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Research. 41: 10228-40. PMID 24049078 DOI: 10.1093/nar/gkt827 |
0.305 |
|
| 2013 |
Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S, Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB. The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5740-8. PMID 23969937 DOI: 10.1158/1078-0432.CCR-13-1712 |
0.802 |
|
| 2013 |
Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G. Triple negative breast cancers have a reduced expression of DNA repair genes. Plos One. 8: e66243. PMID 23825533 DOI: 10.1371/journal.pone.0066243 |
0.548 |
|
| 2013 |
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. British Journal of Cancer. 108: 1587-92. PMID 23579222 DOI: 10.1038/bjc.2013.151 |
0.781 |
|
| 2013 |
Samarajeewa NU, Yang F, Docanto MM, Sakurai M, McNamara KM, Sasano H, Fox SB, Simpson ER, Brown KA. HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Research : Bcr. 15: R30. PMID 23566437 DOI: 10.1186/bcr3410 |
0.371 |
|
| 2013 |
McCormack M, Rosa CS, Murphy M, Fox SB. HER2-positive breast cancer metastatic to intracranial meningioma: a case report. Journal of Clinical Pathology. 66: 633-4. PMID 23436926 DOI: 10.1136/jclinpath-2013-201455 |
0.325 |
|
| 2012 |
Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. Bmc Cancer. 12: 510. PMID 23146383 DOI: 10.1186/1471-2407-12-510 |
0.312 |
|
| 2012 |
Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget. 3: 893-906. PMID 23097685 |
0.344 |
|
| 2012 |
Nguyen BT, Deb S, Fox S, Hill P, Collins M, Chua BH. A prospective pathologic study to define the clinical target volume for partial breast radiation therapy in women with early breast cancer. International Journal of Radiation Oncology, Biology, Physics. 84: 1116-22. PMID 22543203 DOI: 10.1016/j.ijrobp.2012.02.038 |
0.321 |
|
| 2012 |
Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I, McKay MJ, Fox SB. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Research : Bcr. 14: R69. PMID 22537934 DOI: 10.1186/bcr3176 |
0.335 |
|
| 2012 |
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, ... ... Fox S, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 134-47. PMID 22144499 DOI: 10.1158/1055-9965.Epi-11-0775 |
0.356 |
|
| 2012 |
Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America. 109: 2766-71. PMID 21768359 DOI: 10.1073/pnas.1104778108 |
0.6 |
|
| 2011 |
Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, ... ... Fox S, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 13: R110. PMID 22053997 DOI: 10.1186/Bcr3052 |
0.323 |
|
| 2011 |
Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, ... ... Fox SB, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute. Monographs. 2011: 147-51. PMID 22043063 DOI: 10.1093/jncimonographs/lgr037 |
0.64 |
|
| 2011 |
Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 111-5. PMID 22043055 DOI: 10.1093/jncimonographs/lgr035 |
0.524 |
|
| 2011 |
Generali D, Symmans WF, Berruti A, Fox SB. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 99-102. PMID 22043052 DOI: 10.1093/jncimonographs/lgr030 |
0.554 |
|
| 2011 |
Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, Bersiga A, Dogliotti L, Fox SB, Harris AL, Bottini A. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. Journal of the National Cancer Institute. Monographs. 2011: 67-70. PMID 22043044 DOI: 10.1093/jncimonographs/lgr029 |
0.611 |
|
| 2011 |
Huang KT, Takano EA, Mikeska T, Byrne DJ, Dobrovic A, Fox SB. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Research and Treatment. 130: 319-29. PMID 21755341 DOI: 10.1007/s10549-011-1657-1 |
0.372 |
|
| 2011 |
Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, Fox SB. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research : Bcr. 13: R47. PMID 21521526 DOI: 10.1186/bcr2869 |
0.55 |
|
| 2011 |
Shaida N, Chan P, Turley H, Jones CM, Kanga S, Ritchie RW, Malone PR, Harris AL, Fox SB. Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis. The Journal of Urology. 185: 1513-8. PMID 21334674 DOI: 10.1016/j.juro.2010.12.001 |
0.662 |
|
| 2011 |
Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DD, Harvey KF. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30: 2810-22. PMID 21317925 DOI: 10.1038/onc.2011.8 |
0.323 |
|
| 2011 |
Chan P, Möller A, Liu MC, Sceneay JE, Wong CS, Waddell N, Huang KT, Dobrovic A, Millar EK, O'Toole SA, McNeil CM, Sutherland RL, Bowtell DD, Fox SB. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research : Bcr. 13: R19. PMID 21306611 DOI: 10.1186/bcr2828 |
0.452 |
|
| 2011 |
Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research : Bcr. 13: R16. PMID 21291529 DOI: 10.1186/bcr2825 |
0.826 |
|
| 2011 |
Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski JM, Verschoor S, Millar EK, van der Spek P, Reis-Filho JS, Ramsay RG, O'Toole SA, McNeil CM, Sutherland RL, ... ... Fox SB, et al. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research : Bcr. 13: R9. PMID 21255398 DOI: 10.1186/bcr2814 |
0.338 |
|
| 2011 |
Davies JQ, Lin HH, Stacey M, Yona S, Chang GW, Gordon S, Hamann J, Campo L, Han C, Chan P, Fox SB. Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncology Reports. 25: 619-27. PMID 21174063 DOI: 10.3892/Or.2010.1117 |
0.405 |
|
| 2011 |
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 157-67. PMID 21076464 DOI: 10.1038/modpathol.2010.200 |
0.35 |
|
| 2011 |
McKay M, Xu H, Yan M, Yan Y, Ramsay R, Sutherland R, Fox S. 755 poster ENHANCED RAD21 COHESIN EXPRESSION CONFERS POOR PROGNOSIS AND RESISTANCE TO CHEMOTHERAPY IN HIGH GRADE LUMINAL, BASAL AND HER2 BREAST CANCERS Radiotherapy and Oncology. 99: S299. DOI: 10.1016/S0167-8140(11)70877-5 |
0.362 |
|
| 2010 |
Margariti N, Fox SB, Bottini A, Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? Breast Cancer Research and Treatment. 128: 599-606. PMID 20945086 DOI: 10.1007/s10549-010-0986-9 |
0.508 |
|
| 2010 |
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research : Bcr. 12: 207. PMID 20804570 DOI: 10.1186/bcr2607 |
0.376 |
|
| 2010 |
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment. 123: 795-804. PMID 20680681 DOI: 10.1007/s10549-010-1063-0 |
0.821 |
|
| 2010 |
Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, ... ... Fox S, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research : Bcr. 12: R46. PMID 20604919 DOI: 10.1186/Bcr2603 |
0.311 |
|
| 2010 |
Yan M, Rayoo M, Takano EA, Fox SB. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Research and Treatment. 126: 395-405. PMID 20490651 DOI: 10.1007/s10549-010-0941-9 |
0.374 |
|
| 2010 |
Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Research. 70: 1573-84. PMID 20145130 DOI: 10.1158/0008-5472.CAN-09-3237 |
0.601 |
|
| 2010 |
Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment. 124: 79-88. PMID 20054642 DOI: 10.1007/s10549-009-0714-5 |
0.634 |
|
| 2010 |
Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment. 123: 661-77. PMID 19960244 DOI: 10.1007/S10549-009-0653-1 |
0.305 |
|
| 2010 |
Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, et al. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer. Journal International Du Cancer. 126: 1445-53. PMID 19676041 DOI: 10.1002/ijc.24826 |
0.444 |
|
| 2009 |
Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer. 101: 1749-57. PMID 19844231 DOI: 10.1038/sj.bjc.6605368 |
0.823 |
|
| 2009 |
Huang KT, Dobrovic A, Fox SB. No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. Bmc Research Notes. 2: 194. PMID 19778456 DOI: 10.1186/1756-0500-2-194 |
0.328 |
|
| 2009 |
Yan M, Rayoo M, Takano EA, Thorne H, Fox SB. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. British Journal of Cancer. 101: 1168-74. PMID 19724277 DOI: 10.1038/sj.bjc.6605287 |
0.388 |
|
| 2009 |
Rayoo M, Yan M, Takano EA, Bates GJ, Brown PJ, Banham AH, Fox SB. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. Journal of Clinical Pathology. 62: 896-902. PMID 19622517 DOI: 10.1136/jcp.2009.065169 |
0.361 |
|
| 2009 |
Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banham AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1046-51. PMID 19188178 DOI: 10.1158/1078-0432.CCR-08-1507 |
0.798 |
|
| 2009 |
Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, ... ... Fox SB, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer. 100: 405-11. PMID 19165203 DOI: 10.1038/sj.bjc.6604844 |
0.784 |
|
| 2009 |
Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 227-34. PMID 19064988 DOI: 10.1200/JCO.2007.13.7083 |
0.797 |
|
| 2009 |
Rayoo M, Yan M, Takano EA, Fox SB. BRCA1 associated breast cancers are frequently positive for ER and its cytoplasmic expression confers a poor prognosis Pathology. 41: 51. DOI: 10.1097/01268031-200941001-00102 |
0.371 |
|
| 2008 |
Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2673-80. PMID 18451231 DOI: 10.1158/1078-0432.CCR-07-1046 |
0.794 |
|
| 2008 |
Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nature Genetics. 40: 650-5. PMID 18408720 DOI: 10.1038/ng.117 |
0.327 |
|
| 2008 |
Shaida N, Launchbury R, Boddy JL, Jones C, Campo L, Turley H, Kanga S, Banham AH, Malone PR, Harris AL, Fox SB. Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. The Prostate. 68: 336-43. PMID 18163427 DOI: 10.1002/pros.20707 |
0.815 |
|
| 2008 |
Bates GJ, Fox SB, Han C, Launchbury R, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Research and Treatment. 111: 453-9. PMID 18026833 DOI: 10.1007/s10549-007-9812-4 |
0.746 |
|
| 2007 |
Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Research : Bcr. 9: 216. PMID 18190723 DOI: 10.1186/bcr1796 |
0.657 |
|
| 2007 |
Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Research : Bcr. 9: R89. PMID 18096060 DOI: 10.1186/bcr1838 |
0.788 |
|
| 2007 |
Gunningham SP, Currie MJ, Morrin HR, Tan EY, Turley H, Dachs GU, Watson AI, Frampton C, Robinson BA, Fox SB. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. The Journal of Pathology. 212: 335-44. PMID 17487938 DOI: 10.1002/path.2174 |
0.648 |
|
| 2007 |
Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL, Fox SB. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. The Prostate. 67: 1091-8. PMID 17477366 DOI: 10.1002/pros.20583 |
0.821 |
|
| 2007 |
Fox SB, Launchbury R, Bates GJ, Han C, Shaida N, Malone PR, Harris AL, Banham AH. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. The Prostate. 67: 623-9. PMID 17328069 DOI: 10.1002/pros.20538 |
0.407 |
|
| 2007 |
Generali D, Fox SB, Berruti A, Moore JW, Brizzi MP, Patel N, Allevi G, Bonardi S, Aguggini S, Bersiga A, Campo L, Dogliotti L, Bottini A, Harris AL. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 550-8. PMID 17255277 DOI: 10.1158/1078-0432.CCR-06-1266 |
0.79 |
|
| 2007 |
Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 467-74. PMID 17255267 DOI: 10.1158/1078-0432.CCR-06-1466 |
0.798 |
|
| 2007 |
Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P, Harris AL. EGFR mutations in exons 18-21 in sporadic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 203-5. PMID 17220285 DOI: 10.1093/annonc/mdl322 |
0.733 |
|
| 2007 |
Lau YS, Danks L, Sun SG, Fox S, Sabokbar A, Harris A, Athanasou NA. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Research and Treatment. 105: 7-16. PMID 17151927 DOI: 10.1007/s10549-006-9438-y |
0.353 |
|
| 2007 |
Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4562-8. PMID 16899602 DOI: 10.1158/1078-0432.CCR-05-2690 |
0.821 |
|
| 2007 |
Generali DG, Berruti A, Fox SB, Brizzi M, Bonardi S, Milani M, Bersiga A, Dionisio R, Dogliotti L, Bottini A, Harris AL. Down-regulation of HIF-1α expression by letrozole in ER+ve breast cancer patients Journal of Clinical Oncology. 25: 510-510. DOI: 10.1200/JCO.2007.25.18_SUPPL.510 |
0.775 |
|
| 2007 |
Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First International Consensus on the Methodology of Lymphangiogenesis Quantification in Solid Human Tumors Cheminform. 38. DOI: 10.1002/CHIN.200725276 |
0.317 |
|
| 2006 |
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5373-80. PMID 17135638 DOI: 10.1200/JCO.2006.05.9584 |
0.734 |
|
| 2006 |
Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer. 95: 1611-25. PMID 17117184 DOI: 10.1038/Sj.Bjc.6603445 |
0.42 |
|
| 2006 |
Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer. 13: 921-30. PMID 16954440 DOI: 10.1677/erc.1.01216 |
0.829 |
|
| 2006 |
Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3623-8. PMID 16877730 DOI: 10.1200/JCO.2005.04.5773 |
0.769 |
|
| 2006 |
Bacon AL, Fox S, Turley H, Harris AL. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene. 26: 132-41. PMID 16799636 DOI: 10.1038/sj.onc.1209761 |
0.794 |
|
| 2006 |
Fox SB. Quantitative angiogenesis in breast cancer. Methods in Molecular Medicine. 120: 161-87. PMID 16491601 DOI: 10.1385/1-59259-969-9:161 |
0.344 |
|
| 2006 |
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute. 98: 262-72. PMID 16478745 DOI: 10.1093/jnci/djj052 |
0.513 |
|
| 2006 |
Generali DG, Fox S, Buffa FM, Berruti A, Brizzi M, Allevi G, Bonardi S, Dogliotti L, Bottini A, Harris A. Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients Journal of Clinical Oncology. 24: 618-618. DOI: 10.1200/jco.2006.24.18_suppl.618 |
0.583 |
|
| 2006 |
Sooriakumaran P, Macanas-Pirard P, Fox S, Coley H, Bucca G, Lovell D, Henderson A, Smith C, Langley S, Laing R. A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer Journal of Clinical Oncology. 24: 4563-4563. DOI: 10.1200/JCO.2006.24.18_SUPPL.4563 |
0.313 |
|
| 2005 |
Ah-See ML, Burcombe RJ, Daley FM, Richman PI, Padhani AR, Bentzen SM, Fox SB, Harris AL, Makris A. Evaluation of tumour microvessel density & pericyte coverage index following neoadjuvant chemotherapy in primary breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 655. PMID 27946122 DOI: 10.1200/Jco.2005.23.16_Suppl.655 |
0.528 |
|
| 2005 |
Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer Clinical Cancer Research. 11: 7658-7663. PMID 16278385 DOI: 10.1158/1078-0432.CCR-05-0460 |
0.811 |
|
| 2005 |
Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Research and Treatment. 93: 237-46. PMID 16172796 DOI: 10.1007/S10549-005-5157-Z |
0.493 |
|
| 2005 |
Campo L, Turley H, Han C, Pezzella F, Gatter KC, Harris AL, Fox SB. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. The Journal of Pathology. 205: 585-91. PMID 15776477 DOI: 10.1002/path.1740 |
0.796 |
|
| 2005 |
Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 112: 413-30. PMID 15563306 DOI: 10.1111/j.1600-0463.2004.apm11207-0803.x |
0.426 |
|
| 2005 |
Boddy J, Fox S, Cheng H, Hurley H, Brown P, Malone P, Banham A, Harris A. 885Co-expression of the forkhead transcription factor, FOXPI with the androgen receptor in human prostate cancer, support its role as a potential co-regulator of this receptor European Urology Supplements. 4: 224. DOI: 10.1016/S1569-9056(05)80889-9 |
0.75 |
|
| 2005 |
Boddy JL, Fox SB, Cheng H, Hurley H, Brown P, Malone PR, Harris AL. 237: Expression of the Androgen Receptor in Prostate Cancer is related to Vascular Endothelial Growth Factor and Hypoxia Inducible Factors 1: and 2 Journal of Urology. 173: 65-65. DOI: 10.1016/s0022-5347(18)34502-6 |
0.774 |
|
| 2004 |
Sotiriou C, Paesmans M, Harris A, Colozza MA, Fox S, Taylor M, Sorre A, Martiat P, Cardoso F, Piccart M. Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9504. PMID 28016802 DOI: 10.1200/jco.2004.22.14_suppl.9504 |
0.33 |
|
| 2004 |
Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7965-71. PMID 15585631 DOI: 10.1158/1078-0432.Ccr-04-0063 |
0.697 |
|
| 2004 |
Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Research. 64: 6563-70. PMID 15374969 DOI: 10.1158/0008-5472.CAN-03-3176 |
0.773 |
|
| 2004 |
Fox SB, Bragança J, Turley H, Campo L, Han C, Gatter KC, Bhattacharya S, Harris AL. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Research. 64: 6075-81. PMID 15342390 DOI: 10.1158/0008-5472.Can-04-0708 |
0.721 |
|
| 2004 |
Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, Fox SB. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. British Journal of Cancer. 91: 954-8. PMID 15328513 DOI: 10.1038/sj.bjc.6602059 |
0.741 |
|
| 2004 |
Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, Robinson BA, Fox SB. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. Journal of Clinical Pathology. 57: 829-34. PMID 15280403 DOI: 10.1136/jcp.2003.015644 |
0.343 |
|
| 2004 |
Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3521-7. PMID 15161711 DOI: 10.1158/1078-0432.CCR-03-0461 |
0.73 |
|
| 2004 |
Fox SB, Turley H, Cheale M, Blázquez C, Roberts H, James N, Cook N, Harris A, Gatter K. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. The Journal of Pathology. 202: 313-20. PMID 14991896 DOI: 10.1002/path.1520 |
0.656 |
|
| 2004 |
Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C, Harris AL. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. The Journal of Pathology. 201: 573-80. PMID 14648660 DOI: 10.1002/path.1486 |
0.783 |
|
| 2004 |
Ord JJ, Cranston D, Harris AL, Campo L, Turley H, Allen P, Fox S, Davies DR. 773: C-KIT and CK7 Immunohistochemistry in the Differential Diagnosis of Renal Cell Carcinoma, A Study of 111 Cases Journal of Urology. 171: 205-205. DOI: 10.1016/s0022-5347(18)38022-4 |
0.582 |
|
| 2003 |
Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Research and Treatment. 81: 137-47. PMID 14572156 DOI: 10.1023/A:1025702330207 |
0.495 |
|
| 2003 |
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America. 100: 10393-8. PMID 12917485 DOI: 10.1073/Pnas.1732912100 |
0.459 |
|
| 2003 |
Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. The Journal of Pathology. 200: 183-94. PMID 12754739 DOI: 10.1002/path.1339 |
0.799 |
|
| 2003 |
Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. British Journal of Cancer. 88: 718-25. PMID 12618881 DOI: 10.1038/sj.bjc.6600807 |
0.549 |
|
| 2002 |
Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, Chong W, Harris AL, Fox SB. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. The Journal of Pathology. 198: 502-10. PMID 12434420 DOI: 10.1002/path.1228 |
0.791 |
|
| 2002 |
Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. European Journal of Cancer (Oxford, England : 1990). 38: 1564-79. PMID 12142044 |
0.337 |
|
| 2002 |
Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. The Lancet. Oncology. 2: 278-89. PMID 11905783 DOI: 10.1016/S1470-2045(00)00323-5 |
0.462 |
|
| 2001 |
Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. The Journal of Pathology. 195: 236-43. PMID 11592104 DOI: 10.1002/path.931 |
0.537 |
|
| 2001 |
Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. The Journal of Pathology. 193: 325-32. PMID 11241411 DOI: 10.1002/path.814 |
0.534 |
|
| 2000 |
Kakolyris S, Fox SB, Koukourakis M, Giatromanolaki A, Brown N, Leek RD, Taylor M, Leigh IM, Gatter KC, Harris AL. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. British Journal of Cancer. 82: 844-51. PMID 10732757 DOI: 10.1054/bjoc.1999.1010 |
0.545 |
|
| 2000 |
Fox SB, Gatter KC, Leek RD, Harris AL, Chew KL, Mayall BH, Moore DH. More about: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. Journal of the National Cancer Institute. 92: 161-2. PMID 10639519 DOI: 10.1093/jnci/92.2.161 |
0.703 |
|
| 1999 |
Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 10: 707-13. PMID 10442194 DOI: 10.1023/A:1008303614441 |
0.537 |
|
| 1998 |
Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. British Journal of Cancer. 77: 2246-51. PMID 9649140 DOI: 10.1038/bjc.1998.373 |
0.712 |
|
| 1998 |
Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID, Gatter KC, Harris AL. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. British Journal of Cancer. 77: 1169-73. PMID 9569057 DOI: 10.1038/bjc.1998.194 |
0.53 |
|
| 1997 |
Fox SB, Harris AL. The epidermal growth factor receptor in breast cancer Journal of Mammary Gland Biology and Neoplasia. 2: 131-141. PMID 10882299 |
0.472 |
|
| 1997 |
Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. The Journal of Pathology. 182: 414-20. PMID 9306962 DOI: 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q |
0.584 |
|
| 1997 |
Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. Journal of the National Cancer Institute. 89: 1044-9. PMID 9230886 DOI: 10.1093/JNCI/89.14.1044 |
0.701 |
|
| 1997 |
Fox SB, Harris AL. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy Investigational New Drugs. 15: 15-28. PMID 9195286 DOI: 10.1023/A:1005714527315 |
0.424 |
|
| 1997 |
Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 8: 271-5. PMID 9137797 DOI: 10.1023/A:1008280110558 |
0.696 |
|
| 1997 |
Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. The Journal of Pathology. 181: 207-12. PMID 9120727 DOI: 10.1002/(SICI)1096-9896(199702)181:2<207::AID-PATH758>3.0.CO;2-4 |
0.482 |
|
| 1997 |
Engels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. Exs. 79: 113-56. PMID 9002231 DOI: 10.1007/978-3-0348-9006-9_6 |
0.497 |
|
| 1997 |
Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Human Pathology. 27: 1149-55. PMID 8912823 DOI: 10.1016/S0046-8177(96)90307-X |
0.765 |
|
| 1996 |
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. European Journal of Cancer (Oxford, England : 1990). 32: 2474-84. PMID 9059336 DOI: 10.1016/S0959-8049(96)00379-6 |
0.534 |
|
| 1996 |
Harris AL, Zhang H, Moghaddam A, Fox S, Scott P, Pattison A, Gatter K, Stratford I, Bicknell R. Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment. 38: 97-108. PMID 8825127 DOI: 10.1007/BF01803788 |
0.532 |
|
| 1996 |
Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. The Journal of Pathology. 179: 232-7. PMID 8774475 DOI: 10.1002/(sici)1096-9896(199607)179:3<232::aid-path505>3.0.co;2-a |
0.397 |
|
| 1996 |
Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. British Journal of Cancer. 73: 275-80. PMID 8562330 DOI: 10.1038/bjc.1996.49 |
0.725 |
|
| 1996 |
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. The Journal of Pathology. 177: 275-83. PMID 8551390 DOI: 10.1002/PATH.1711770310 |
0.709 |
|
| 1996 |
Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Research and Treatment. 36: 219-26. PMID 8534869 DOI: 10.1007/BF00666042 |
0.693 |
|
| 1995 |
Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. The Journal of Urology. 154: 237-41. PMID 7776437 DOI: 10.1016/S0022-5347(01)67286-0 |
0.443 |
|
| 1995 |
Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. The Journal of Pathology. 176: 183-90. PMID 7636628 DOI: 10.1002/path.1711760212 |
0.624 |
|
| 1995 |
Harris AL, Fox S, Leek R, Zhang H, Scott P, Bicknell R, Gatter K. Breast cancer angiogenesis: therapy target and prognostic factor. European Journal of Cancer (Oxford, England : 1990). 831-2. PMID 7543767 DOI: 10.1016/0959-8049(95)00129-7 |
0.72 |
|
| 1995 |
Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 92: 998-1002. PMID 7532308 DOI: 10.1073/pnas.92.4.998 |
0.687 |
|
| 1995 |
Macaulay VM, Fox SB, Zhang H, Whitehouse RM, Leek RD, Gatter KC, Bicknell R, Harris AL. Breast cancer angiogenesis and tamoxifen resistance Endocrine Related Cancer. 2: 97-103. DOI: 10.1677/erc.0.0020097 |
0.705 |
|
| 1995 |
Caffo O, Barbareschi M, Veronese S, Pezzella F, Leek R, Fox S, Harris A, Dalla Palma P. 686 BCL2 expression in node-negative breast carcinoma: A study on a series of 190 cases with long-term follow-up European Journal of Cancer. 31: S143. DOI: 10.1016/0959-8049(95)95936-Z |
0.75 |
|
| 1994 |
Harris AL, Fox S, Bicknell R, Leek R, Relf M, LeJeune S, Kaklamanis L. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer. 74: 1021-5. PMID 8039135 DOI: 10.1002/1097-0142(19940801)74:3+<1021::AID-CNCR2820741508>3.0.CO;2-1 |
0.716 |
|
| 1994 |
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment. 29: 41-49. PMID 8018963 DOI: 10.1007/Bf00666180 |
0.454 |
|
| 1994 |
Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. British Journal of Urology. 74: 762-6. PMID 7530131 DOI: 10.1111/j.1464-410X.1994.tb07122.x |
0.396 |
|
| 1994 |
Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment. 29: 109-116. PMID 7517221 DOI: 10.1007/Bf00666186 |
0.744 |
|
| 1993 |
Rogers S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptor in male breast carcinoma. Human Pathology. 24: 148-51. PMID 8381763 DOI: 10.1016/0046-8177(93)90293-p |
0.329 |
|
| 1993 |
Fox S, Stuart N, Smith K, Brunner N, Harris A. High levels of uPA and PA1 are associated with highly angiogenic breast carcinomas The Breast. 2: 206. DOI: 10.1016/0960-9776(93)90148-9 |
0.45 |
|
| 1993 |
Fox S, Gatter K, Bicknell R, Going J, Cooke T, Harris A. Endothelial cell proliferation in human breast carcinoma The Breast. 2: 206. DOI: 10.1016/0960-9776(93)90147-8 |
0.482 |
|
| 1992 |
Fox SB, Rogers S, Day CA, Underwood JC. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. The Journal of Pathology. 166: 13-8. PMID 1538271 DOI: 10.1002/path.1711660104 |
0.339 |
|
| 1991 |
Fox SB, Day CA, Rogers S. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. Journal of Clinical Pathology. 44: 960-1. PMID 1684366 DOI: 10.1136/jcp.44.11.960 |
0.32 |
|
| Show low-probability matches. |